ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
Dow Jones
38,239.66
0.40%
US Dollar vs MXN
17.1601
0.00%
Brent Oil
88.165
0.00%
Bitcoin
63,886.86
0.75%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Regeneron Pharmaceuticals Inc (REGN)

  7. Regeneron Pharmaceuticals Inc (REGN) Noticias

REGN Regeneron Pharmaceuticals Inc

883.20
-7.48 (-0.84%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Regeneron Pharmaceuticals Inc REGN NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-7.48 -0.84% 883.20 23:00:06
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
881.72 875.225 887.4794 883.20 890.68
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
25/4/202406:00GLOBERegeneron and Mammoth Biosciences Collaborate to Pursue..
24/4/202409:05GLOBERegeneron to Showcase Progress in Advancing Novel..
22/4/202416:54GLOBERegeneron to Highlight Advances in Genetic Medicine Research..
16/4/202406:18IHMARKETNEWSEricsson Soars with 66% Net Profit Growth; Live Nation Under..
11/4/202406:24IHMARKETNEWSCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’..
07/4/202415:00GLOBELinvoseltamab Pivotal Data Presented at AACR Reinforce High..
01/4/202415:05GLOBERegeneron to Report First Quarter 2024 Financial and..
25/3/202406:00GLOBERegeneron Provides Update on Biologics License Application..
12/3/202422:55PRNUSHigh School Seniors Win $1.8 Million at Regeneron Science..
12/3/202420:30GLOBEHigh School Seniors Win $1.8 Million at Regeneron Science..
11/3/202406:00GLOBEPraluent® (alirocumab) Injection Receives FDA Approval to..
08/3/202406:00GLOBEEYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet..
05/3/202415:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202415:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202415:14EDGAR2Form 144 - Report of proposed sale of securities
28/2/202415:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202415:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202415:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202415:34EDGAR2Form 144 - Report of proposed sale of securities
26/2/202415:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202415:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202415:07EDGAR2Form 144 - Report of proposed sale of securities
26/2/202415:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202414:25EDGAR2Form 144 - Report of proposed sale of securities
23/2/202415:04EDGAR2Form 144 - Report of proposed sale of securities
23/2/202400:00GLOBEDupixent® (dupilumab) sBLA Accepted for FDA Priority Review..
22/2/202416:10EDGAR2Form 144 - Report of proposed sale of securities
22/2/202415:06EDGAR2Form 144 - Report of proposed sale of securities
21/2/202406:00GLOBELinvoseltamab BLA for Treatment of Relapsed/Refractory..
20/2/202415:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202415:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202423:59GLOBEJapan First in the World to Approve Dupixent® (dupilumab)..
14/2/202416:08EDGAR2Form 144 - Report of proposed sale of securities
12/2/202415:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202415:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202417:19EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
09/2/202415:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202415:04EDGAR2Form 144 - Report of proposed sale of securities
09/2/202411:22EDGAR2Form 144 - Report of proposed sale of securities
08/2/202415:56EDGAR2Form 144 - Report of proposed sale of securities
08/2/202415:26EDGAR2Form 144 - Report of proposed sale of securities
08/2/202415:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/2/202415:01EDGAR2Form 3 - Initial statement of beneficial ownership of..
07/2/202416:59EDGAR2Form 144 - Report of proposed sale of securities
07/2/202416:07EDGAR2Form 144 - Report of proposed sale of securities
07/2/202415:35EDGAR2Form 144 - Report of proposed sale of securities
06/2/202415:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202415:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202415:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202415:05GLOBERegeneron Announces Investor Conference Presentations

Su Consulta Reciente

NASDAQ
REGN
Regeneron Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados